Xencor Gets CD20xCD3 Bispecific Back From J&J
Still Partnered On Two Antibodies
Deal snapshot: J&J decided to return global rights to platotamab, a Phase II-ready CD20xCD3 bispecific antibody for hematological cancers, but remains partnered with Xencor on candidates for prostate cancer and B-cell malignancies.
